
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nabilone
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Ault Global Holdings
Deal Size : $3.0 million
Deal Type : Acquisition
Ault Global Holdings Announces Agreement to Acquire up to 40% of Adtech Pharma, Inc.
Details : NB-110 comprises of a synthetic cannabinoid Nabilone in the absence of any preservative and its formulation mimics a human tear to drive efficacious delivery through the cornea to the retina and optical nerves in the back of eye.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Nabilone
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Ault Global Holdings
Deal Size : $3.0 million
Deal Type : Acquisition
